The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria : PROERCAN study. Rationale and design
Copyright © 2020 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: Blood pressure (BP) control is fundamental to the care of patients with chronic kidney disease (CKD), and is relevant at all stages of CKD. Renin-angiotensin-aldosterone system (RAAS) blockers have shown to be effective, not only in BP control but also in reducing proteinuria and slowing CKD progression. However, there is a lack of evidence for recommending RAAS blockers in elderly patients with CKD without proteinuria. The primary outcome of the present study is to evaluate the impact of RAAS blockers on CKD progression in elderly patients without proteinuria.
MATERIALS AND METHODS: The PROERCAN trial (trial registration, NCT03195023) is a multicentre open-label, randomized controlled clinical trial with 110 participants over 65 years-old with hypertension and CKD stages 3-4 without proteinuria. Patients will be randomized in a 1:1 ratio to either receive RAAS blockers or other antihypertensive drugs, and will be followed up for three years. Primary outcome is the estimated glomerular filtration rate (eGFR) decline at 3 years. Secondary outcomes include BP control, renal and cardiovascular events, and mortality.
RESULTS AND CONCLUSIONS: The design of this trial is presented here. The results will show if antihypertensive treatment with RAAS blockers has an impact on CKD progression in elderly patients without proteinuria. Any differences in BP control, cardiovascular events, and mortality with each antihypertensive treatment will be also clarified.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Hipertension y riesgo vascular - 37(2020), 3 vom: 16. Juli, Seite 101-107 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
García-Prieto, A M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.04.2021 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hipert.2020.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307447650 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307447650 | ||
| 003 | DE-627 | ||
| 005 | 20240321234847.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hipert.2020.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1338.xml |
| 035 | |a (DE-627)NLM307447650 | ||
| 035 | |a (NLM)32156479 | ||
| 035 | |a (PII)S1889-1837(20)30027-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a García-Prieto, A M |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of renin-angiotensin-aldosterone system blockers on the progression of chronic kidney disease in hypertensive elderly patients without proteinuria |b PROERCAN study. Rationale and design |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.04.2021 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: Blood pressure (BP) control is fundamental to the care of patients with chronic kidney disease (CKD), and is relevant at all stages of CKD. Renin-angiotensin-aldosterone system (RAAS) blockers have shown to be effective, not only in BP control but also in reducing proteinuria and slowing CKD progression. However, there is a lack of evidence for recommending RAAS blockers in elderly patients with CKD without proteinuria. The primary outcome of the present study is to evaluate the impact of RAAS blockers on CKD progression in elderly patients without proteinuria | ||
| 520 | |a MATERIALS AND METHODS: The PROERCAN trial (trial registration, NCT03195023) is a multicentre open-label, randomized controlled clinical trial with 110 participants over 65 years-old with hypertension and CKD stages 3-4 without proteinuria. Patients will be randomized in a 1:1 ratio to either receive RAAS blockers or other antihypertensive drugs, and will be followed up for three years. Primary outcome is the estimated glomerular filtration rate (eGFR) decline at 3 years. Secondary outcomes include BP control, renal and cardiovascular events, and mortality | ||
| 520 | |a RESULTS AND CONCLUSIONS: The design of this trial is presented here. The results will show if antihypertensive treatment with RAAS blockers has an impact on CKD progression in elderly patients without proteinuria. Any differences in BP control, cardiovascular events, and mortality with each antihypertensive treatment will be also clarified | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Albuminuria | |
| 650 | 4 | |a Ancianos | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Enfermedad renal crónica | |
| 650 | 4 | |a Hipertensión | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Renin–angiotensin-system | |
| 650 | 4 | |a Sistema renina-angiotensina | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 700 | 1 | |a Verdalles, Ú |e verfasserin |4 aut | |
| 700 | 1 | |a de José, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Verde, E |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo, D |e verfasserin |4 aut | |
| 700 | 1 | |a Aragoncillo, I |e verfasserin |4 aut | |
| 700 | 1 | |a Linares, T |e verfasserin |4 aut | |
| 700 | 1 | |a Barbieri, D |e verfasserin |4 aut | |
| 700 | 1 | |a Goicoechea, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hipertension y riesgo vascular |d 2015 |g 37(2020), 3 vom: 16. Juli, Seite 101-107 |w (DE-627)NLM250932563 |x 1989-4805 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g number:3 |g day:16 |g month:07 |g pages:101-107 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hipert.2020.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |e 3 |b 16 |c 07 |h 101-107 | ||